Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157339
Status:
COMPLETED
Last Update Posted:
2019-09-17
First Post:
2005-09-07
Brief Title:
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Pivotal Open-Label Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder HIIP Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 3 open-label randomized study to evaluate the safety and efficacy of the LillyAlkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD Patients will be treated for 12 months with a 2 month follow up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H7U-MC-IDAS | OTHER | Eli Lilly and Company | None |